QuantRx Biomedical Corporation is an emerging leader in the development of products for advanced diagnosis of serious disease and health conditions. With synergistic expertise in the discovery of diagnostic platforms and the commercialization of products for use by medical professionals, institutions, and consumers, QuantRx is focused on providing more accurate, reliable, and faster diagnoses that result in improved patient care.

The QuantRx strategy is one of sustained growth and targets significant market opportunities estimated to be in excess of $4 billion worldwide.

The Company’s technology portfolio, with more than two dozen patents, patents pending and licenses, covers the major medical diagnostic markets with unique breakthrough products.

Through its affiliate company FluoroPharma (www.fluoropharma.com), QuantRx is developing important molecular imaging agents for positron emission tomography (PET) and fluorescence imaging, addressing significant unmet medical needs by providing clinicians with important tools for early discovery and assessment of disease. Initial application is in the treatment of cardiovascular disease.

Through its affiliate company Genomics USA, Inc.(www.genomicsusa.com), QuantRx is developing genome-based microarray chips for the laboratory-based diagnostic market.

Patented PAD technology for diagnosis and treatment of women's health concerns and other medical needs.

QuantRx has corporate offices in Doylestown, Pennsylvania, and its research and development center in Portland, Oregon. The Company holds a significant position in FluoroPharma, Inc., a Boston-based molecular imaging company, and in Genomics USA, Inc., a Chicago-based developer of microarray technology for DNA testing.